Fang Ruoxin, Gong Jun, Liao Zhengkai
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, Hubei, China.
Front Oncol. 2023 Jul 21;13:1220745. doi: 10.3389/fonc.2023.1220745. eCollection 2023.
The pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of NSCLC with rapid progression and poor prognosis, and is resistant to conventional chemotherapy. Most PSC cases have potential targetable genomic alterations. Approximately 7% of PSC patients have BRAF mutations, and the efficacy of dabrafenib and trametinib in BRAF mutated PSC is unclear.
Our report describes a patient with mutated BRAF PSC who underwent surgery and adjuvant chemotherapy early but quickly relapsed. Both chemotherapy and immunotherapy were ineffective for him, combined dabrafenib and trametinib produced a 6-month progression-free survival, and a partial response was observed in the tumor response evaluation. As a result of financial pressure, he stopped taking the targeted drugs, and his disease rapidly progressed.
Dabrafenib combined with trametinib provides partial remission in patients with advanced PSC with BRAF mutations, and large-scale NGS panels could offer more options for PSC treatment.
肺肉瘤样癌（PSC）是一种罕见且侵袭性强的非小细胞肺癌亚型，进展迅速，预后不良，对传统化疗耐药。大多数PSC病例存在潜在的可靶向基因组改变。约7%的PSC患者存在BRAF突变，达拉非尼和曲美替尼在BRAF突变型PSC中的疗效尚不清楚。
我们的报告描述了一名BRAF突变型PSC患者，该患者早期接受了手术和辅助化疗，但很快复发。化疗和免疫治疗对他均无效，联合使用达拉非尼和曲美替尼产生了6个月的无进展生存期，并且在肿瘤反应评估中观察到部分缓解。由于经济压力，他停止服用靶向药物，疾病迅速进展。
达拉非尼联合曲美替尼可使晚期BRAF突变型PSC患者获得部分缓解，大规模NGS检测可为PSC治疗提供更多选择。
